Compugen Boosts Cancer Treatment Potential with New Patent for COM902 and Antibody Combinations Compugen has received a new U.S. patent for COM902, enabling its use in combination therapies with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.

Compugen Boosts Cancer Treatment Potential with New Patent for COM902 and Antibody Combinations #Israel #cancer_therapy #Compugen #COM902 #Holon